Overcoming Challenges In AAV And LV Viral Vector Manufacturing

The field of cell and gene therapies (CGTs) is experiencing explosive growth, bringing these potential cures closer to patients. This rapid advancement necessitates the development of scalable and efficient manufacturing processes to deliver these therapies quickly and safely. Leveraging our industry-leading expertise in viruses and viral vectors, we've developed next-generation AAV and LV platforms. These platforms will further strengthen our partnerships and empower our clients to accelerate the progress of their cell and gene therapies.

Building on our proven track record, which includes the production of one of the first commercially approved CGT products by the FDA and EMA, we are committed to bringing the next generation of these life-changing therapies to market. Mathias Kahl, Director of Process Development at IDT Biologika, shares insights on overcoming challenges in AAV and LV viral vector manufacturing.